{"transactions":[{"id":758680,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:05:26.000Z","date":"2026-05-22","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":8.78,"expiration_date":"2036-05-22","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-26-026429","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000149315226026429/ownership.xml","form_type":"4"}},{"id":758679,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T21:05:26.000Z","date":"2026-05-22","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 6,250 restricted stock units (\"RSUs\") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the \"2027 Annual Meeting\") is held, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":181004,"source":{"system":"sec-edgar","filing":"0001493152-26-026429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000149315226026429/ownership.xml","form_type":"4"}},{"id":1103719,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T20:57:33.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":33000,"derivative":{"exercise_price":2.24,"expiration_date":"2035-06-20","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001641172-25-016109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000164117225016109/ownership.xml","form_type":"4"}},{"id":1471996,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T21:45:10.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":33000,"derivative":{"exercise_price":2.04,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001493152-24-024821","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000149315224024821/ownership.xml","form_type":"4"}},{"id":1508935,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T21:25:55.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":74241,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity."}],"balance_after":174754,"source":{"system":"sec-edgar","filing":"0001493152-24-020777","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000149315224020777/ownership.xml","form_type":"4"}},{"id":1508934,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T21:25:55.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":87740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted Stock Awards which will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":100740,"source":{"system":"sec-edgar","filing":"0001493152-24-020777","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000149315224020777/ownership.xml","form_type":"4"}},{"id":1781010,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T21:20:59.000Z","date":"2023-09-12","kind":"purchase","planned":false,"acquired":true,"shares":13000,"price":2.9609,"value":38491.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This figure is the weighted average sales price of multiple trades ranging from $2.90 to $3.25 per share. The Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, Immix Biopharma, Inc. or any security holder of Immix Biopharma, Inc. full information about the number of shares sold at each separate price upon request."}],"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001493152-23-032664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000149315223032664/ownership.xml","form_type":"4"}},{"id":1808507,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-08-14T20:15:35.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest monthly over 12 months from the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":1.86,"expiration_date":"2033-08-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-23-028471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000149315223028471/ownership.xml","form_type":"4"}},{"id":1852134,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:08.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21526,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,... (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,... (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":29.02,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":21526},"source":{"system":"sec-edgar","filing":"0000899243-23-015753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000089924323015753/doc4.xml","form_type":"4"}},{"id":1852133,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:08.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,... (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,... (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":36.32,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":1083},"source":{"system":"sec-edgar","filing":"0000899243-23-015753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000089924323015753/doc4.xml","form_type":"4"}},{"id":1852132,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:00:08.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,... (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,... (Continued in Footnote 3)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"derivative":{"exercise_price":6.7,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-23-015753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000089924323015753/doc4.xml","form_type":"4"}},{"id":1852131,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T20:00:08.000Z","date":"2023-06-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2674,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 2,174 restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. (\"Merck\") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the \"Merger Consideration\"), without interest,... (Continued in Footnote 3)"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-015753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000089924323015753/doc4.xml","form_type":"4"}},{"id":1884535,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T21:38:13.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":2174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of restricted stock units (\"RSUs\") granted under the Issuer's 2021 Incentive Award Plan (the \"2021 Plan\").  Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting.  The RSUs shall vest in full upon the earlier to occur of (i) the first anniversary of the date of grant, (ii) the Issuer's next occurring annual meeting of stockholders, or (iii) a Change of Control (as defined in the 2021 Plan), subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":2674,"source":{"system":"sec-edgar","filing":"0001209191-23-031170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000120919123031170/doc4.xml","form_type":"4"}},{"id":2206299,"issuer":{"id":4958,"kind":"organization","name":"Immix Biopharma, Inc."},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-07-18T10:10:32.000Z","date":"2022-07-14","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest monthly over 12 months from date of grant."}],"balance_after":53500,"derivative":{"exercise_price":2.64,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001493152-22-019513","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000149315222019513/ownership.xml","form_type":"4"}},{"id":2261786,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T23:18:02.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":21526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full upon the earlier to occur of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":21526,"derivative":{"exercise_price":29.02,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":21526},"source":{"system":"sec-edgar","filing":"0001209191-22-031171","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000120919122031171/doc4.xml","form_type":"4"}},{"id":2510584,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-17T02:17:34.000Z","date":"2021-11-14","kind":"grant","acquired":true,"shares":1083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the first anniversary of the vesting commencement date measured from November 14, 2021, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":1083,"derivative":{"exercise_price":36.32,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":1083},"source":{"system":"sec-edgar","filing":"0001209191-21-064940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000120919121064940/doc4.xml","form_type":"4"}},{"id":2786178,"issuer":{"id":112175,"kind":"organization","name":"Prometheus Biosciences, Inc.","symbol":"RXDX"},"owners":[{"id":43158,"kind":"person","name":"Adams Helen C.","position":1,"cik":"0001488486","reported_name":"Adams Helen C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-17T01:47:51.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":500,"price":19,"value":9500.0,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0001209191-21-021216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488486/000120919121021216/doc4.xml","form_type":"4"}}]}